SYGNIS, ECACC Collaborate
News Sep 23, 2016
SYGNIS AG has announced that Navicyte Scientific, part of SYGNIS Group in the US, and the European Collection of Authenticated Cell Cultures (ECACC), part of Public Health England, an agency of the United Kingdom Department of Health have entered into a collaboration agreement for licensing and distributing the Caco-2 cell line to commercial companies.
Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line from SYGNIS in the US and afterwards will provide the Caco-2 materials directly.
“We are very happy about this collaboration agreement with ECACC,” Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG commented.
“Up to now, the majority of our Caco-2 business has been in the US. This new collaboration will expand our Caco-2 activities to Europe and increase the commercialization potential for SYGNIS, as ECACC is very active in the distribution of cell lines to researchers. ECACC has a large customer data base and they will include our Caco-2 cell line in their project developments.”
Caco-2 cells were developed by the Memorial Sloan Kettering Cancer Center (MSKCC) and are now available from ECACC. ECACC is authorized to distribute these cells to the scientific community for the use in research and SYGNIS currently holds an exclusive license from the MSKCC for the commercial use of the Caco-2 cell line.
The primary use of this cell line is in pharmaceutical drug development, particularly for absorption of orally bioavailable molecules and transporter studies. The Caco-2 assay is well characterized and is the recognized gold standard for absorption assays. It is part of many standard preclinical (ADME) substance characterization packages used by the pharmaceutical industry.
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018